Alprenololum [Inn-Latin] en es it fr

Alprenololum [Inn-Latin] Brand names, Alprenololum [Inn-Latin] Analogs

Alprenololum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Alprenololum [Inn-Latin] Chemical_Formula


Alprenololum [Inn-Latin] RX_link

No information avaliable

Alprenololum [Inn-Latin] fda sheet

Alprenololum [Inn-Latin] msds (material safety sheet)

Alprenololum [Inn-Latin] Synthesis Reference

Brandstrom et al., Acta Pharm. Suecica 3, 303 (1966)

Alprenololum [Inn-Latin] Molecular Weight

249.349 g/mol

Alprenololum [Inn-Latin] Melting Point

107-109 oC

Alprenololum [Inn-Latin] H2O Solubility

547 mg/L

Alprenololum [Inn-Latin] State


Alprenololum [Inn-Latin] LogP


Alprenololum [Inn-Latin] Dosage Forms


Alprenololum [Inn-Latin] Indication

For the treatment of hypertension, angina, and arrhythmia

Alprenololum [Inn-Latin] Pharmacology

Alprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Alprenololum [Inn-Latin] Absorption

No information avaliable

Alprenololum [Inn-Latin] side effects and Toxicity

LD50=597.0 mg/kg (Orally in rats)

Alprenololum [Inn-Latin] Patient Information

No information avaliable

Alprenololum [Inn-Latin] Organisms Affected

Humans and other mammals